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Abstract: Marine and salmon polar lipids (PLs) extracted by conventional extractions with
non-food-grade solvents (CE-salmon-PLs) possess antithrombotic bioactivities against platelet-activating
factor (PAF) and thrombin. Similar effects of food-grade-extracted (FGE) marine PLs have not yet
been reported. In this study, food-grade solvents were used to extract PLs from Irish organic farmed
salmon (Salmo salar) fillets (FGE-salmon-PLs), while their antithrombotic bioactivities were assessed
in human platelets induced by platelet aggregation agonists (PAF/thrombin). FGE-salmon-PLs were
further separated by thin layer chromatography (TLC) into lipid subclasses, and the antithrombotic
bioactivities of each subclass were also assessed. LC-MS was utilized to elucidate the structure-activity
relationships. FGE-salmon-PLs strongly inhibited PAF-induced platelet aggregation, while their
relevant anti-thrombin effects were at least three times more potent than the previously reported
activities of CE-salmon-PLs. TLC-derived lipid fractions corresponding to phosphatidylcholines
(PC) and phosphatidylethanolamines (PE) were the most bioactive lipid subclasses obtained,
especially against thrombin. Their LC-MS analysis elucidated that they are diacyl- or alkyl-acyl-
PC and PE moieties baring ω3 polyunsaturated fatty acids (PUFA) at their sn-2 position, such as
eicosapentaenoic acid (EPA) or docosahexaenoic acid (DHA). Our results concerning the potent
antithrombotic effects of FGE-salmon-PLs against both PAF and thrombin pathways strongly suggest
that such food-grade extracts are putative candidates for the development of novel cardioprotective
supplements and nutraceuticals.
Keywords: salmon; polar lipids; platelet aggregation; platelet-activating factor (PAF); thrombin;
phosphatidylcholine; phosphatidylethanolamine; LC-MS; EPA; DHA; PUFA; phospholipids
1. Introduction
Marine polar lipids (PLs) have exhibited several beneficial activities against inflammation, thrombosis,
and related disorders [1–4]. In contrast to triglycerides and esters, marine PLs have superior
incorporation into cell membranes and plasma lipoproteins, including high-density lipoprotein
(HDL) [1–4]. Therefore, they not only possess higher bioavailability of their ω3 polyunsaturated
fatty acids (PUFA), but they can more efficiently affect the biofunctionality of plasma lipoproteins and
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the activities of several plasma membrane receptors related to important pathways of inflammation
and thrombosis [1–5], such as the receptor for platelet-activating factor (PAF) [4–6].
PAF, namely 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine [6], is a unique physiologically
active signalling phospholipid activator of many cell types, including platelets, and a potent mediator
of inflammation and related diseases, such as atherosclerosis and cardiovascular diseases (CVD), renal
disorders, cancer, persistent infections, etc. [5]. Another important mediator of platelet pathophysiology
and atherothrombosis is thrombin [7,8]. Thrombin is a serine protease that participates in coagulant
catalytic processes, such as the conversion of fibrinogen into fibrin and the activation of the V, VIII, XI,
and XIII coagulation factors [7,8], as well as the activation of many cell types and platelets including
platelet aggregation [7]. Such soluble platelet agonists are produced during coagulation (e.g., thrombin)
and inflammation (e.g., PAF) and play a critical role via G-protein-coupled receptors (GPCR) in
platelet activation and thrombus formation [7]. These mediators also present in high concentrations in
atherosclerotic plaques and atherothrombotic events [6,8].
Previously, these two pathways were considered independent, and therapeutic approaches were
mainly focused on each individual pathway. However, there is a crosstalk between inflammation and
coagulation systems in chronic diseases, whereby inflammation leads to the activation of coagulation,
and coagulation also considerably affects inflammatory activity [6]. For example, PAF has been found
to synergistically augment thrombin-induced platelet activation [9], while in melanoma metastasis
the PAF/PAF-receptor pathway interrelates with pathways related to thrombin and its receptor
(PAR-1) [10]. Vice versa, thrombin stimulation of endothelial cells through its receptor PAR-1
results in the activation of calcium-independent phospholipase A2 (iPLA2). Thus, the synthesis
of membrane phospholipid-derived inflammatory mediators such as PAF, arachidonic acid (AA),
and prostaglandins [11] are all considered to be central in both the initiation and propagation of
the inflammatory response [6]. Moreover, PAF produced by endothelial cells treated with thrombin
can further stimulate and influence the activation of circulating effector cells, such as platelets and
polymorphonuclear leukocytes [12], while the interaction of the endothelium with activated circulating
blood cells takes place in both physiologic conditions and in syndromes of vascular injury [6,12].
As a result, the study of bioactive molecules and compounds, especially of natural origin, with
both anti-PAF and anti-thrombin activities is of significant importance. Marine PLs have demonstrated
strong anti-inflammatory and antithrombotic activities by inhibiting the PAF/PAF-receptor-related
pathways and thus PAF activities [4,5,13–16], but also by modulating its metabolism towards
homeostatic PAF levels [17,18]. The inhibitory effects of marine PLs against PAF may be directly
related to their effect on PAF-receptor or indirectly by their lipid rafts that are able to influence the
PAF-receptor lipid-membrane microenvironment, or both cases may happen simultaneously, which
seem to be the most probable scenario, thus explaining their synergistic effect [4,5,16].
Through these mechanistic effects, marine PLs have exhibited in vitro and in vivo beneficial
anti-atherogenic and cardioprotective properties [4,5,13–19]. It has recently been demonstrated that
PLs extracted from fillets of Irish organic farmed salmon (Salmo salar), also possess strong in vitro
antithrombotic bioactivities against platelet aggregation, mostly through their strong inhibitory effects
against the PAF pathway, but with less potent effects towards the thrombin pathway [16]. These
salmon PL extracts were previously extracted from salmon fillets, by utilising conventional extraction
methods (CE) based on non-food-grade solvents [16,20,21].
However, to the best of our knowledge, there is no reported evidence for similar antithrombotic
bioactivities of marine PLs extracted from fish species using food-grade solvents, according to European
Union (EU) legislation for edible fish oil extractions. For the first time, the in vitro antithrombotic
effects of salmon PL extracts that were extracted from Irish organic farmed salmon (Salmo salar) fillets
using food-grade solvents (FGE-salmon-PLs), against both the PAF and thrombin pathways of platelet
aggregation are presented. FGE-salmon-PLs were further separated into several lipid subclasses
and the biological activity of each subclass was assessed against PAF and thrombin-induced platelet
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aggregation. LC-MS analysis was conducted on the most bioactive lipid subclasses in order to elucidate
the structure–activity relationships.
The present study is a continuation of previous research towards the development of novel
PL-based cardioprotective food supplements and nutraceuticals from sustainable marine sources.
2. Results
2.1. Yield of FGE-salmon-PLs
Total lipids (TL) of all samples (n = 6) of salmon fillets from the same batch of farmed salmon were
extracted using food-grade solvents according to EU legislation for extracting fish oils and further
separated into neutral lipids (NL) and PLs by a counter-current distribution, also using food-grade
solvents. The amounts of FGE-salmon-PLs obtained (expressed as g of lipids per 100 g of fish tissue)
are given in Table 1. They were found to be similar (non-statistically significant difference: p > 0.05)
with that of previously reported outcomes for salmon PLs extracted by conventional extractions
(CE-salmon-PLs) using non-food-grade solvents, such as chloroform and petroleum ether [16].
Table 1. Yield of FGE-salmon-PLs of Irish organic farmed salmon (Salmo salar) fillets, and the inhibitory
effect of these lipids towards the PAF and thrombin pathways of platelet aggregation in hPRP,
in comparison with the previously reported data of the CE-salmon-PLs. Reproduced with permission
from Tsoupras et al. [16].
Yield & Bioactivity of Salmon-PLs CE-Salmon-PLs & FGE-Salmon-PLs
Yield of PLs $ (g) ± SD 0.86 ± 0.36 0.61 ± 0.21
IC50 † (µg) ± SD against PAF–induced platelet aggregation 45 ± 22 86 ± 18 *
IC50 † (µg) ± SD against thrombin-induced platelet aggregation 382 ± 39 102 ± 29 *
$ Expressed as mean values of g of lipids per 100 g of salmon fillet (mean ± SD, n = 6); † IC50 values reflect the
inhibitory strength of each PL extract towards PAF/thrombin-induced platelet aggregation in hPRP and is expressed
as mean values of µg of lipids in the aggregometer cuvette that cause 50% inhibition on PAF/thrombin-induced
platelets aggregation in hPRP ± standard deviation; & the yield of extraction and the IC50 values of the
CE-salmon-PLs against PAF and thrombin-induced aggregation of hPRP are reproduced in this table (2nd column)
as reported by Tsoupras, Lordan, Demuru, Shiels, Saha, Nasopoulou, and Zabetakis [16], in order to facilitate
comparisons between the newly acquired data of the present study (3rd column). * Statistical significant difference
(p < 0.05) when compared with the previously reported IC50 values of the CE-salmon-PLs extracts [16].
2.2. TLC Analysis of FGE-Salmon-PLs
FGE-salmon-PLs were further separated into several PL subclasses and fractions by preparative
TLC analysis, as previously described [16]. It was found that within the FGE-salmon-PLs, several
phospholipid subclasses exist determined by the TLC bands when compared to specific standards
of phospholipid subclasses, as shown in Figure 1A. TLC bands 1–6 of the FGE-salmon-PLs were
found to possess similar Rf values to those of lyso-phosphatidylcholines (L-PC), polar lipids of
the sphingomyelin family (SM), phosphatidylcholines (PC), lyso-phosphatidylethanolamines (L-PE),
phosphatidylethanolamines (PE), and cardiolipin (CL) respectively, see Figure 1A. These results are
in accordance with previously reported results of similar TLC analyses of the CE-salmon-PLs and
CE-marine-PLs derived from several other fish species [15,16].
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Figure 1. TLC analysis of both food-grade-extracted (FGE)-salmon-polar lipids (PLs) and conventional extractions with non-food-grade solvents (CE)-salmon-PLs (A), and 
inhibitory effects (IC50 values) of lipid fractions (TLC bands) against platelet aggregation induced by platelet-activating factor (PAF) (B) or thrombin (C). (A): 1st column 
(from left to right): Separation of a standard mixture of egg-yolk phospholipids, 2nd column: Separation of CE-salmon-PLs, 3rd and 4th columns: Separation of FGE-
salmon-PLs. (B and C): Results are expressed as mean values of IC50 against PAF/thrombin-induced platelet aggregation; the blue bars depict the IC50 values of each TLC 
band of the CE-salmon-PL extracts, while the orange bars depict the IC50 values of each TLC band of the FGE salmon-PL extracts. The IC50 values of TLC bands of the CE-
salmon-PLs against the PAF-induced aggregation of human platelet-rich plasma (hPRP) are reproduced in this figure (blue bars in B) reproduced with permission according 
to Tsoupras et al. [16]. * indicates statistically significant differences (p < 0.05) between the bioactivity of FGE-salmon-PL fractions in comparison to that of CE-salmon-PL 
fractions. # indicates statistically significant differences (p < 0.05) between the bioactivity of FGE-salmon-PE fraction against thrombin in comparison to the relative 
bioactivity of all the other FGE-salmon-PLs fractions. Lipid fractions of TLC bands 1 and 4 (corresponding to lyso-phosphatidylcholines (PC) and Lyso-
phosphatidylethanolamines (PE) did not exhibit inhibitory bioactivities. The results are representative of six independent experiments, in order to ensure reproducibility. 
Figure 1. TLC analysis of both food-grade-extracted (FGE)-salmon-polar lipids (PLs) and conventional extractions with non-food-grade solvents (CE)-salmon-PLs (A),
and inhibitory effects (IC50 values) of lipid fractions (TLC bands) against platelet aggregation induced by platelet-activating factor (PAF) (B) or thrombin (C). (A): 1st
column (from left to righ ): Separation of a stan ard mixture f egg-yo k phospholipi s, 2nd column: Separation of CE-salm n PLs, 3rd and 4th columns: Separation
of FGE-salmon-PLs. (B and C): Results are expressed as mean values of IC50 agains PAF/thrombin-induc d platelet aggregation; the blue ba s depict the IC50 values
of each TLC band of the CE-salmon-PL extracts, while the orange bar depict the IC50 va es of each TLC band of the FGE salmon-PL extracts. The IC50 values of TLC
ba ds of the CE-salmon-PL gainst the PAF-induced ggregation of human platelet-rich plasma (hPRP) are rep oduced in this figure (blue bars in B) reproduced with
permission accordi g to Tsoupras et al. [16]. * i dicates statistically significant differences (p < 0.05) between the bioactivity of FGE-salmon-PL fractions in comparison
to that of CE-salmon-PL fractions. # indicates statistically significant differences (p < 0.05) betwe n the bioactivity of FGE-salmon-PE fraction against thr mbin in
com arison to the relative bioactivity of all the other FGE-salmon-PLs fractions. Lipid fractions of TLC bands 1 a d 4 (corresponding to ly -phosphatidylcho ines
(PC) and Lyso-pho pha dy ethanolamines (PE) did not exhibit inhibitory bioactivities. The results are representative of six independent experiments, in orde to
ensure reproducibility.
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2.3. Antithrombotic Effects of FGE-Salmon-PLs and Their Lipid Subclasses against Human
Platelet Aggregation
The in vitro antithrombotic effects of FGE-salmon-PLs against aggregation of human platelets
was evaluated by the IC50 values of their inhibitory effects towards platelet aggregation induced
by well-established aggregation agonists such as PAF and thrombin in human platelet-rich plasma
(hPRP), as previously described [16]. The IC50 values reflect the inhibitory strength of each salmon
PL extract, because low IC50 values indicate stronger inhibition of PAF-induced/thrombin-induced
platelet aggregation for a given salmon PLs’ concentration. The mean IC50 value of the inhibitory effect
of all the FGE-salmon-PLs extracts against PAF-induced platelet aggregation was found to be within
the same range (non-statistically significant difference: p > 0.05) with their relative IC50 value towards
the thrombin-induced platelet aggregation, see Table 1. Both of these IC50 values are comparable with
relative IC50 values of bioactive PLs extracted from other fish species, but also from other food samples
and microorganisms, which exhibited similar anti-inflammatory and antithrombotic effects towards
PAF-induced activation and aggregation of platelets [13–15,22–24].
With respect to salmon, the FGE-salmon-PLs extracts exhibited lower inhibitory effects against
the PAF pathway of human platelet aggregation in comparison with the previously reported anti-PAF
effects of the CE-salmon-PLs extracts [16]. However, the IC50 values of the FGE-salmon-PLs
against PAF-induced hPRP aggregation were in the same order of magnitude as that of the CE
salmon-PLs. On the other hand, FGE-salmon-PLs exhibited much higher inhibitory effects towards
the thrombin-pathway of human platelet aggregation than the previously reported anti-thrombin
effects of the CE-salmon-PLs (p < 0.05) [16]. The IC50 values of FGE-salmon-PLs against thrombin-induced
hPRP aggregation were also comparable with relative IC50 values of bioactive CE-PLs extracts from
other fish products (Greek avgotaracho) and cyanobacteria, which exhibited similar effects towards
thrombin-induced aggregation of platelets [22,23].
Furthermore, the PLs subclasses in each of the TLC bands, which were obtained by the TLC
separation of the FGE-salmon-PLs, were also tested for their ability to inhibit platelet aggregation of
hPRP induced by PAF and thrombin, see Figure 1. The TLC separation of both FGE-salmon-PLs and
CE-salmon-PLs in TLC bands (TLC-derived lipid fractions corresponding to specific lipid subclasses)
is depicted in Figure 1A, while the IC50 values of the bioactive lipid fractions of each TLC band are
given in Figure 1B,C. The FGE-salmon-PLs extract exhibited inhibitory properties, that are attributed
to almost all the polar lipid fractions (Bands 2, 3, 5, 6) apart from lipid fractions 1 and 4 that did not
exhibit such an effect, see Figure 1B,C. None of the fractions exhibited any aggregatory properties
of hPRP.
Similarly to previously reported results of the CE-salmon-PLs [19], the TLC bands 3 and 5 of the
FGE-salmon-PLs, which have similar Rf values to those of PC and PE lipid subclasses, see Figure 1A,
exhibited potent inhibitory effects towards PAF-induced aggregation of hPRP, see Figure 1B. These
results are in accordance with previously reported outcomes against PAF for these PL subclasses
(PC and PE) present in the same TLC bands of PLs derived from salmon and several other fish
species [14,15]. However, TLC band 2 of the FGE-salmon-PLs, which has a similar Rf value to that of
the sphingomyelin (SM) family band, also exhibited potent inhibitory effects towards PAF-induced
aggregation of hPRP, see Figure 1B, which was much higher than the previously reported relative one
of the CE-salmon-PLs [16] (p < 0.01). TLC band 6 of the FGE-salmon-PLs exhibited a similar anti-PAF
effect with the previously reported relative activity of the CE-salmon-PLs [16], see Figure 1B.
Moreover, the TLC bands 2, 3, and 5 of the FGE-salmon-PLs, which have similar Rf values
to those of the SM family, PC, and PE lipid subclasses, exhibited much higher inhibitory effects
towards thrombin-induced platelet aggregation of hPRP than the relative activity of the CE-salmon-PLs
(p < 0.01 in all these comparisons) (Figure 1C). Furthermore, the fraction of the SM family of the
FGE-salmon-PLs exhibited higher anti-PAF and anti-thrombin activities in comparison to the reported
anti-PAF and anti-thrombin activities of the fraction of the SM family of the CE-salmon-PLs [16].
However, the anti-thrombin effects of the fraction of the SM family of the FGE-salmon-PLs was found
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to be similar to the relative anti-thrombin effects of the PC fraction (p > 0.05) and significantly lower to
that of the PE fraction (p < 0.05) of the FGE-salmon-PLs. In addition, the anti-PAF effects of the fraction
of the SM family of the FGE-salmon-PLs were found to be slightly lower (but not significantly lower,
p > 0.05) than the relative effect of the PC fraction, whereas it was significantly lower (p < 0.05) than
the relative effect of the PE fraction of the FGE-salmon-PLs. It should be mentioned that TLC band 5
of the FGE-salmon-PLs (that corresponds to the PE subclass) exhibited the highest inhibitory effect
towards thrombin-induced aggregation of hPRP, when compared with the relative activities of either
all the other TLC bands of the FGE-salmon-PLs (p < 0.05) or all the TLC bands of the CE-salmon-PLs
(p < 0.01).
2.4. LC-MS Analysis of FGE-salmon-PLs and Structure–Activity Relationships
FGE-salmon-PLs and the most bioactive TLC fractions (corresponding to the PC and PE
lipid subclasses), were further analysed by LC-MS as previously described [16]. Characteristic
chromatograms of the HPLC separation for both TLC fractions of PC and PE lipid subclasses of
the FGE-salmon-PLs are depicted in Figure 2A,B respectively. Several peaks with specific retention
times were observed in both cases. By using a C18 reverse phase column in the LC-MS analysis,
the separation of the lipids is mostly based on the length of the non-polar acyl- or alkyl-groups in
combination with their degree of unsaturation. Thus, PC and PE species baring PUFA were separated
within short retention times (1–3.5 min), rather than other PC and PE species baring more saturated
and longer chains within their structures that seem to be eluted in higher retention times (8–15 min).Mar. Drugs 2018, 16, x  7 of 24 
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821.63 (with a relative demethylated negative ion [M−CH3]− at 805.98 m/z) and the 1-O-alkyl-(18:0)-2-
sn-alkyl-(22:6,DHA)-3-PC, see Figure 3B, with a theoretical mass of 819.61 (with a relative 
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bioactive PE lipid subclass of the FGE-salmon-PLs, such as the 1-O-alkyl-(16:0)-2-sn-alkyl-
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negative ion [M − H]− at 748.51 m/z), the 1-O-alkyl-(20:0)-2-sn-alkyl-(20:5,EPA)-3-PE, see Figure 4C, 
Figure 2. Representative HPLC chromatograms of the most bioactive lipid subclasses of the
FGE-salmon-PLs. (A) Depicts a representative chromatogram of the TLC fraction corresponding to the
phosphatidylcholines (PC) lipid subclass of the FGE-salmon-PLs, whereas (B) depicts a representative
chromatogram of the TLC fraction corresponding to the phosphatidylethanolamines (PE) lipid subclass
of the FGE-salmon-PLs.
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By applying quadrupole time-of-flight mass spectrometry (Q-TOF) simultaneously with the HPLC
separation for each one of these peaks, unique MS data were obtained for each peak leading to complete
structural elucidations of novel structures for these PC and PE moieties. The characterisation of these
molecules was based on the acquired m/z values of the dehydrogenated negative ions [M − H]− for
PE and free fatty acids (FFA), and the demethylated negative ions [M − CH3]− for PC as previously
described [16], and further verified by using the LIPID MAPS: Nature Lipidomics Gateway (www.
lipidmaps.org), based on the lowest delta values during identification, in combination with their fatty
acids contents that were acquired by the LC-MS analyses of the FFA derived by the saponification
of FGE-salmon-PLs.
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Figure 3. Representative mass spectra of PC species present in the relative TLC fraction corresponding
to the PC lipid subclass of the FGE-salmon-PLs eluted over short retention times (1.0–3.5 min).
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With respect to the LC-MS structural analysis of the PC and PE fractions, survey scans in the
negative ion mode between 600 and 1000 m/z of MS1 demonstrated a specific pattern of molecular
species for PC, see Figure 3, and PE, see Figure 4, eluted within short retention times (1–3.5 min). It is
proposed that many of these are diacyl-PC and diacyl-PE species containing 14:0, 16:0, 16:1, 18:0, 18:1,
18:2, 20:0, 20:1, 20:2, 20:3, 22:0, 22:1, 22:2, etc., fatty acids at the sn-1 position and mostlyω3 PUFA at
the sn-2 position, such as the 22:6 fatty acid (DHA) or the 20:5 fatty acid (EPA). 1-O-alkyl-2-sn-acyl-PC
moieties also seem to be present in less but considerable quantities, usually with ω3 PUFA at the
sn-2 position, including DHA and EPA. shown as squares in Figures 3 and 4, respectively. The most
representative novel mass spectra of these acyl-acyl PC and PE moieties, but also of the alkyl-acyl PC
and PE moieties are shown in Figures 3 and 4, respectively.Mar. Drugs 2018, 16, x  9 of 24 
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In detail, specific alkyl-acyl-PC molecules baring either DHA or EPA at the sn-2 position seem to
be present in the TLC fraction of the bioactive PC lipid subclass of the FGE-salmon-PLs, such as the
1-O-alkyl-(20:0)-2-sn-alkyl-(20:5,EPA)-3-PC, as shown in Figure 3A, with a theoretical mass of 821.63
(with a relative demethylated negative ion [M−CH3]− at 805.98 m/z) and the 1-O-alkyl-(18:0)-2-sn-
alkyl-(22:6,DHA)-3-PC, see Figure 3B, with a theoretical mass of 819.61 (with a relative demethylated
negative ion [M−CH3]− at 805.30 m/z). Furthermore, specific alkyl-acyl-PE molecules baring either
DHA or EPA at the sn-2 position seem also to be present in the TLC fraction of the bioactive PE lipid
subclass of the FGE-salmon-PLs, such as the 1-O-alkyl-(16:0)-2-sn-alkyl-(22:6,DHA)-3-PE, see Figure 4C,
with a theoretical mass of 749.54 (with a relative dehydrogenated negative ion [M − H]− at 748.51 m/z),
the 1-O-alkyl-(20:0)-2-sn-alkyl-(20:5,EPA)-3-PE, see Figure 4C, with a theoretical mass of 779.58 (with a
relative dehydrogenated negative ion [M − H]− at 779.44 m/z), the 1-O-alkyl-(24:0)-2-sn-alkyl-(22:6,
DHA)-3-PE, see Figure 4D, with a theoretical mass of 887.73 (with a relative dehydrogenated negative
ion [M − H]− at 887.56 m/z), and the 1-O-alkyl-(20:0)-2-sn-alkyl-(22:6,DHA)-3-PE, see Figure 4E, with a
theoretical mass of 791.55 (with a relative dehydrogenated negative ion [M − H]− at 790.55 m/z), or
the 1-O-alkyl-(18:1)-2-sn-alkyl-(20:5,EPA)-3-PE, see Figure 4E, with the same theoretical mass of 791.55
(with a same relative dehydrogenated negative ion [M − H]− at 790.55 m/z).
Notably, PC and PE species eluted in higher retention times (8–15 min), seem to have longer and
more saturated carbon chains of their acyl-moieties. MS data of these diacyl-PC and diacyl-PE species
(with longer and more saturated fatty chains at both the sn-1 and sn-2 positions) are not shown, since
such PC and PE species do not seem to possess any effect against platelet aggregation and have not
been previously reported to possess such bioactivity.
Furthermore, the data of the LC-MS-analysis of the FFA composition derived from the
saponification of FGE-salmon-PLs and of both PC and PE fractions are shown in Figure 5. Figure 5A
shows a characteristic chromatogram of the LC-MS analysis of the FFA derived by the saponification
of the FGE-salmon-PLs. Survey scans performed in the negative ion mode between 200 and 1000 m/z
of MS1 showed that in all FGE-salmon-PLs samples, PUFA were the most abundant fatty acid class
(approximately 50% of the total FFA) followed by saturated fatty acids (SFA, approximately 21% of
the total FFA) and monounsaturated fatty acids (MUFA, approximately 14% of the total FFA). More
specifically, salmon TPL contains high amounts ofω3 PUFA, with the most abundant being the EPA
(20:5ω3) and the DHA (22:6ω3), see Figure 5B–D. Specific Lyso-PC and Lyso-PE moieties were also
detected, such as Lyso-PE (16:0/0:0), Lyso-PE (18:1/0:0), Lyso-PE (20:0/0:0), Lyso-PC (O-18:0/0:0),
etc., see Figure 5B,C. These data indicate that ω3 PUFA (EPA and DHA) were released during the
saponification of FGE-salmon-PLs mostly from their sn-2 position. In addition, the most abundant ω6
fatty acids in the FGE-salmon-PLs samples were docosapentaenoic acid (DPA; 22:5ω6), AA (20:4ω6),
and linoleic acid (LA; 18:2ω6), while the most abundant MUFA was oleic acid (18:1 c9) and the most
abundant SFA were palmitic acid (16:0) and stearic acid (18:0), see Figure 5D. The relative ratio of
ω6/ω3 was found to be approximately 2.8/1.
Similarly, the most abundant fatty acids found in the FFA derived from the PC and PE fractions
were the ω3 fatty acids EPA (20:5ω3) and DHA (22:6ω3) and the ω6 fatty acids DPA (22:5ω6) and
linoleic acid (LA; 18:2ω6) from the PUFA, the palmitic acid (16:0) and stearic acid (18:0) from the SFA,
and the oleic acid (18:1 c9) and the palmitoleic acid (16:1 c9) from the MUFA. In addition, the PC
fraction was not found to contain AA (20:4ω6), while the PE fraction contained much less AA than
the FGE-salmon-PLs, implying that the AA contained in the FGE-salmon-PLs is distributed in PLs
subclasses other than PC and PE. Interestingly, both PC and PE fractions were found to be rich in
odd-chain SFA such as the pentadecanoic acid (15:0) and heptadecanoic acid (17:0). The ω3 fatty acid
content of both the PC and PE fractions were similar to that of their content in ω6 fatty acids, and thus
the relative ratios ofω6/ω3 for both fractions were found to be approximately 1.1 and 0.9 respectively,
which were lower than the relative ratio found in the FGE-salmon-PLs extract.
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Overall, our results indicate that the most important acyl-acyl-PC and acyl-acyl-PE moieties, but
also those of the alkyl-acyl PC and alkyl-acyl PE moieties, are those that bareω3 PUFA (i.e., EPA and
DHA) in their sn-2 position of the glycerol backbone. Representative proposed structures of these
molecules are shown in Figure 6.
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3. Discussion
Inflammatory and thrombotic events are implicated in all stages of atherosclerosis and CVD [5].
Apart from endothelial cells and leukocytes, activation and aggregation of platelets is also a key
player to the “crosstalk” that takes place between various cells during vascular physiology and
pathophysiology, and thus during several inflammation-related atherosclerotic and atherothrombotic
events of cardiovascular diseases [5,25]. Several platelet agonists can induce platelet activation and
aggregation, with PAF and thrombin being the most potent agonists [5–8,25].
As a result, the study of bioactive molecules and compounds, especially of natural origin, with
both anti-PAF and anti-thrombin activities is of potential therapeutic value. Indeed, the consumption
of fish oils has improved platelet function, human thrombosis, and haemostasis in several disorders [26–28].
This has primarily been attributed to EPA and DHA through mechanisms related to the eicosanoid
pathways. For example, EPA can replace AA in platelet membrane phospholipids and acts as a
substrate for cyclo-oxygenase [29], whilst DHA, but not EPA, can reduce collagen-induced platelet
aggregation, either through replacement of AA by DHA in platelet phospholipids, through the
inhibition of cyclooxygenase, or through the direct effects of DHA on platelet function independent of
eicosanoid production. [30–32]. Platelets treated with EPA and DHA can modify platelet membranes
and reduce the rate of thrombin generation, which results in reduced platelet procoagulant activity and
thrombus formation [33]. Dietary fish oil supplementation rich in EPA and DHA also reduces collagen
or thrombin-induced platelet aggregation, TXB2 generation from platelets and platelet membrane
fluidity in normolipemic subjects [34]. Dietary supplementation of fish oil (MaxEPA) rich in EPA and
DHA for six weeks resulted in the reduction of PAF synthesis in healthy subjects, while PAF generation
was also reduced in monocyte monolayers in the EPA treatment group only, while PAF synthesis was
increased by AA [35].
On the other hand, administration of theseω3 PUFA (either EPA or DHA) in the form of ethyl
esters was not able to reduce PAF-induced platelet aggregation or affect fibrinolytic and vascular
function [31]. In addition, several recent reviews and meta-analyses have indicated that there is
insufficient evidence for any benefits from ω3 PUFA supplements, in the form of purified fatty acids
or in the form of esters, on reducing the risk for CVD (either on primary or in secondary prevention)
and on lowering the risk of all-cause mortality, cardiac death, sudden death, myocardial infarction,
stroke, or cancer [36–38].
Remarkably, several of these studies have also proposed that the beneficial effect of fish intake on
cerebrovascular risk is likely to be mediated through the interplay of a wide range of nutrients
abundant in fish [4]. Indeed, promising results have been attributed to several PLs of marine
origin [4,5,13–16,18,19,22,23], and of natural origin in general [5,24]. Marine PLs and especially,
those baring ω3 PUFA, possess a plethora of beneficial bioactivities towards inflammation-related
disorders [1–4], including their far superior incorporation into cell membranes and plasma lipoproteins
such as high-density lipoprotein (HDL), compared to the incorporation of marine triglycerides or esters,
and thus they possess higher bioavailability of their bioactiveω3 PUFA in several tissues, including
those with difficult accessibility (i.e., the brain tissue because of the blood–brain barrier) [4,39,40].
Marine PLs possess strong anti-inflammatory and antithrombotic activities against PAF-related
pathways and metabolism [4,5,13–18] and against the thrombin pathways [16,22]. However, in these
previous studies, the bioactive polar lipids were extracted using well-established but conventional
methods (CE-marine-PLs), such as the Bligh and Dyer [20] method and the Galanos and Kapoulas [21]
counter-current distribution, which are based on solvents such as chloroform, methanol, and petroleum
ether. Although these well-established methods are reliable for acquiring a high yield of polar lipids
from various food sources, they are not the panacea for extracting and separating bioactive polar lipids.
To the best of our knowledge, anti-PAF and anti-thrombin activities of polar lipids derived from
marine sources by environmentally clean food-grade extraction methods according to EU legislation
without the use of organic toxic solvents such as chloroform and petroleum ether, have not previously
been reported. However, there have been several studies that have evaluated the effect of using
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food-grade and non-food-grade extraction methods on the fatty acid composition of lipid extracts of
marine origin, especially in phospholipids rich in PUFA such as EPA and DHA [41–43]. However, these
studies did not focus on the bioactivities that such marine-derived PLs may possess. This study is the
first to report that polar lipids derived from salmon using food-grade extraction methods compliant
with current EU legislation (Directive 2009/32/EC) possess strong antithrombotic activities against
both PAF and thrombin-induced human platelet aggregation.
Furthermore, in our study, it was also found that the anti-PAF effects of the FGE-salmon-PLs were
within the same order of magnitude as those previously reported from CE-salmon-PLs [16], while the
anti-thrombin effects of the FGE-salmon-PLs were at least three times more potent than the previously
reported relevant effects of the CE-salmon-PLs.
In addition, specific TLC lipid fractions of the FGE-salmon-PLs corresponding to PC and PE lipid
subclasses exhibited the most potent inhibitory effect against PAF-induced human platelet aggregation,
in comparison to all of the other TLC lipid fractions. These results are in accordance with previously
reported activities against PAF for PC and PE PLs present in the same TLC bands of PLs derived from
CE-salmon-PLs and several other fish species [14,16].
Moreover, for the first time, TLC-derived lipid fractions corresponding to PC and PE lipid subclasses
of the FGE-salmon-PLs exhibited much higher inhibitory effects against the thrombin-induced human
platelet aggregation compared to the anti-thrombin effects of the relative TLC-derived lipid fractions
of PC and PE of the CE-salmon-PLs. These effects can be attributed to the existence of potent
anti-thrombin PC and PE lipid moieties within the FGE-salmon-PLs that are not present within
the CE-salmon-PLs. In order to clarify these differences, structural elucidation of the bioactive PC and
PE lipid fractions of the FGE-salmon-PLs was conducted by LC-MS analysis.
The overall fatty acid profile of the FGE-salmon-PLs and the bioactive PC and PE fraction in this
study have similarities with previously reported salmon lipid profiles [16], but they are also similar
to phospholipids of several other fish and animals [44–48]. Similarly to the obtained results in the
CE-salmon-PLs and in other relative studies in salmon [16,44,45], the FGE-salmon-PLs from Irish
organic farmed salmon were found to contain high levels of ω3 PUFA, with the most abundant ω3
fatty acids being EPA and DHA. However, concerning the observed differences, the PE fraction of
FGE-salmon-PLs was found to be abundant in both EPA and DHA ω3 PUFA, in contrast to the PE
fraction of the CE-salmon-PLs. In addition, in contrast to the CE-salmon-PLs, theω6-PUFA AA was
not present in the PC fraction of the FGE-salmon-PLs, while the PE fraction contained much less AA
than the FGE-salmon-PLs, implying that the AA contained in the FGE-salmon-PLs is distributed in
PLs subclasses other than the PC and PE species.
The ω6/ω3 ratio seems to be a determinant of the platelet adhesion, since supplementation
of fish oil rich in ω3 PUFA with an ω6/ω3 ratio of 0.1 resulted in a reduction of human platelet
adhesiveness stimulated by thrombin or adenosine diphosphate (ADP), whereas supplementation
of soy lecithin with anω6/ω3 ratio of 3.0 resulted in a stimulatory effect on resting and stimulated
platelet adhesion [49]. In the present study, theω3 fatty acid content of the PC and PE fractions was
approximately similar to that of ω6 fatty acids, and thus the ratio of ω6/ω3 PUFA is similar to the
value of 1, which is much lower than that of Westernised diets and is within the range of 5/1–20/1 [50].
It has been reported that high values of this ratio are correlated with a higher risk in cardiovascular
disease and other chronic diseases [50]. Taking this into account, the observed favorable ω6/ω3 ratio
in the bioactive PC and PE fractions of the FGE-salmon-PLs extract may also provide further evidence
for their potential cardioprotective properties, since the lower this ratio is in the diet, the better health
outcomes it provides against such chronic diseases [50]. In addition, the presence of odd-chain fatty
acids, such as pentadecanoic acid (15:0) and heptadecanoic acid (17:0) in the bioactive PC and PE
fractions of the FGE-salmon-PLs extract seems to add to the cardioprotective properties to this extract,
since the presence of such diet-derived odd-chain fatty acids in human plasma PL has been associated
with a decreased risk for CVD and type II diabetes and with favourable effects against the atherogenic
leptin and plasminogen activator inhibitor-1 (PAI-1) levels [51–54].
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Moreover, our LC-MS data also shows that the bioactive PC and PE lipid subclasses are mostly
composed of diacyl-PC and diacyl-PE species containing 14–22 carbon chains with 0, 1, or 2 double
bonds at the sn-1 position andω3 PUFA (mostly either DHA or EPA) or MUFA (such as oleic acid) at
the sn-2 position, while 1-O-alkyl-2-sn-acyl-PC moieties also seem to be present in less but considerable
quantities, usually withω3 PUFA (mostly either DHA or EPA) also at the sn-2 position, see Figures 3,
4 and 6. Our results are in accordance with previously reported research concerning the compositional
analysis and positional distribution of fatty acids (mostly at the sn-2 position) in phospholipids
extracted from different samples of fillets of Atlantic salmon (Salmo salar) that were fed different
diets (i.e., Vegetable and Fish Oil Blends) [44], but also in phospholipids of several other fish, marine
mammals, and krill oil [45–47,55].
The results of this study are partly in accordance with the previously reported structural
elucidation of the bioactive PC lipid subclass of the CE-salmon-PLs [16], since apart from differences
in the bioactivities, some structural differences were also observed. These structural differences are
due to the high abundance of PE moieties (either diacyl-PE or alkyl-acyl-PE) baring EPA and DHA at
their sn-2 position within the most bioactive TLC-derived lipid fraction corresponding to the PE lipid
subclass of the FGE-salmon-PL. These results were not previously observed in the relative PE lipid
subclass of the CE-salmon-PL [16].
In another study [42], different extraction protocols (i.e., a chloroform-free solvent extraction
protocol based on 2-methoxy-2-methylpropane) resulted in similar phospholipid composition and
distribution of fatty acids in seabass brains derived from the well-established conventional method of
Bligh and Dyer [20]. However, it should be noted that the solvents used in the aforementioned study
were different than those used in the present study and they were also not of food-grade standard.
Similarly to the present study, using different solvents and extractions (either food-grade or
conventional) in other marine sources (i.e., seaweed or microalgae) resulted in differences in the lipid
yield [43,56] and the fatty acid composition (i.e., an EtOH-based food-grade extraction achieved an
extract rich in PUFA in contrast to conventional methods) [43]. Furthermore, polar lipid fractions, rich
in phospho- and sphingolipids, obtained from another food source (buttermilk) by using food-grade
ethanol gave a higher yield than those obtained using non-food-grade solvents, while these food-grade
extracted PL fractions exhibited strong antiproliferative bioactivities against several cancer cells,
whereas the non-food-grade extracted lipid extracts and fractions did not provide any significant
anti-proliferative activity in any of the tumour cell lines that were assessed [57]. Therefore, according
to our results and to the relative results of the aforementioned studies, it is suggested that the observed
differences in PC and PE compositions and bioactivities in this study can be attributed to the use of
food-grade extraction solvents and methods.
Concerning the presence of alkyl-acyl-moieties present in both the PC and PE fractions of the
FGE-salmon-PLs, specific alkyl-acyl-PC and alkyl-acyl-PE baring DHA at the sn-2 position also appears
to be present in the TLC fractions of the bioactive PC and PE lipid subclasses of the FGE-salmon-PLs,
namely 1-O-alkyl-(18:0)-2-sn-alkyl-(22:6,DHA)-3-PC and 1-O-alkyl-(16:0)-2-sn-alkyl-(22:6,DHA)-3-PE,
respectively, which were also reported to be present in the relevant TLC fractions of the bioactive PC
and PE lipid subclasses of the CE-salmon-PLs [16]. Interestingly, other alkyl-acyl-PC and alkyl-acyl-PE
baring EPA at the sn-2 position seem also to be present in the TLC fractions of the bioactive PC and PE
lipid subclasses of the FGE-salmon-PLs, such as 1-O-alkyl-(20:0)-2-sn-alkyl-(20:5,EPA)-3-PC and the
1-O-alkyl-(20:0)-2-sn-alkyl-(20:5,EPA)-3-PE, which were not found in the bioactive PC and PE lipid
subclasses of the CE-salmon-PLs [16].
Ether phospholipids (i.e., alkyl-acyl PLs) are usually found in animal tissues and human cells as
minor components, existing together with molecular species of diacyl phospholipids carrying the same
polar head group [58]. Dietary 1-O-alkyl-sn-2-DHA phospholipid species may easily cross through
the intestinal barrier because the rate of hydrolysing sn-1-ether fatty chains/sn-2-DHA phospholipids
by phospholipases can be significantly slowed down [59,60], and most of the species are relatively
stable in the metabolism with high-density lipoprotein (HDL) in vivo, compared with sn-1-acyl fatty
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chains/sn-2-DHA phospholipid species. In addition, such ether phospholipid species, are more
stable in in vivo lipid metabolism, compared with related acyl species, since they can survive from
blocking due to the hydrolysis of phospholipase A1 and phospholipase A1-like enzymes in vivo
metabolism [61–63]. Thus, ω3 PUFA containing ether phospholipid species can be delivered smoothly
and unaffected by lipid metabolism, into plasma lipoproteins and from there to several blood cells and
tissues, including those of difficult accessibility such as the brain.
After being transferred to blood cells such as platelets, alkyl-acyl-phospholipids either possess a
strong inhibitory or a weak agonistic effect or both effects (in different concentrations) against the PAF
pathways of activating cells (including platelet aggregation), because of their structural resemblance
to the PAF molecule, and thus their antagonistic effect for its receptor [5]. Similarly to the previously
described results for the CE-salmon-PLs [16], in the present study, there were no platelet aggregatory
agonistic effects against PAF in all of the PL samples and PL lipid subclasses that were tested. It seems
that the FGE-salmon-PLs possess stronger inhibitory effects against the PAF pathway than any possible
agonistic effect from the constituent lipids in the PL fractions, and in this case, these components are
practically acting mostly as PAF inhibitors.
In general, membrane phospholipids are essential in blood coagulation reactions. The cell membrane,
which is characterised as the “main location” of blood coagulation, is one of its regulatory factors,
and changes in PC and PE content and the phospholipid composition of the cell membrane regulate
the coagulation reactions [64] and the relative responses of the bindings of agonists such as PAF and
thrombin to their receptors. The process of fibrinogen conversion into fibrin and thus the formation
and morphology of fibrin clot is also affected by the charge and phase state of lipids, especially polar
lipids, in membrane surfaces [65]. Thus, coagulation and anti-coagulatory reactions are coordinated
and controlled by changes in the phospholipid composition of the cellular membrane where the
coagulation reaction takes place [64]. In addition, exposure of platelets to thrombin usually induces
a reduction of the amounts of specific phospholipid subclasses, including PC and PE, in the plasma
membrane of thrombin-stimulated platelets [66], while PC and PE have been found to suppress the
rate of thrombin formation and blood coagulation [64]. PE is also physically present at the luminal
endothelial surface, where it tentatively functions as a critical anticoagulant [67], while PE rich in
PUFA enhance the anticoagulant activity of thrombomodulin in endothelial cells [68].
Remarkably, PC and PE rich in EPA also reduce thrombin-induced inflammatory and atherosclerotic
effects [69]. For example, when endothelial cells were cultured in the presence of EPA incorporated in
PC and PE, a significant reduction of the thrombin-induced intracellular release of AA metabolites
and the thrombin-evoked release of endothelin-1 was observed, which is a vasoactive compound
implicated in hypertension, atherosclerosis, and CVD [69]. In addition, supplementation of cod liver oil
rich in EPA in healthy human subjects for at least 14 days resulted in a reduction of thrombin-induced
platelet aggregation and alteration of the FA composition (by incorporating EPA and DHA) in all
PLs subclasses of human platelets [70]. Thus, our results indicating the presence of specific diacyl-
or alkyl-acyl- subspecies of bioactive PC and PE moieties carrying EPA at the sn-2 position, seems to
explain the higher potency of this novel FGE against the thrombin pathways, in contrast to the relative
PC and PE subclasses of the CE-salmon-PL.
Furthermore, a dioleoyl-PE molecule was also present at the PE fraction (with m/z 743.5 and retention
time 2.554 min), while liposomes containing such PE and PC molecules also promote heparin’s
anticoagulant effect against the thrombin-induced coagulation time, among other agonists [71].
Apart from the bioactivities of the PC and PE fractions, we have also found that the SM
family fraction of the FGE-salmon-PLs exhibited higher anti-PAF and anti-thrombin activities in
comparison to the reported anti-PAF and anti-thrombin activities of the fraction of the SM family of the
CE-salmon-PLs [16]. The anti-thrombin effects of the fraction of the SM family of the FGE-salmon-PLs
were found to be similar to the relative anti-thrombin effects of the PC fraction and lower to that of the
PE fraction of the FGE-salmon-PLs. In addition, the anti-PAF effects of the fraction of the SM family
of the FGE-salmon-PLs was found to be slightly lower (but not significantly lower, p > 0.05) than the
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relative effect of the PC fraction, whereas it was significantly lower (p < 0.05) than the relative effect of
the PE fraction of the FGE-salmon-PLs. Furthermore, within the TLC fractions of PC and PE, the LC-MS
analysis revealed that only PC and PE polar lipids exist, whereas in the TLC fraction of SM, there
are usually several other classes of bioactive polar lipids belonging to the SM family that co-migrate
(such as sphingomyelin, cerebrosides, ceramides, gangliosides and several other glyco-sphingolipids).
Moreover, several lipid molecules belonging to the SM family mainly affect thrombin generation [72].
Therefore, more studies are required to elucidate all the species of lipids of the SM family and their
effects on the PAF and thrombin pathways.
The fact that such food and especially, marine-derived bioactive PLs (i.e., PC and PE baring EPA,
DHA and oleic acid at their sn-2 position, and with lowω-6/ω-3 ratio, but also several lipids of the SM
family) can be incorporated with high bioavailability and act synergistically in blood lipoproteins and
membranes of circulating blood cells and endothelial cells [1–4], seems to be related to their abilities to
beneficially alter the functionality of such key cells and pathways of inflammation and coagulation [5].
For example, the addition of farmed Atlantic salmon to the diet twice a week for four weeks at portions
of 180 g and 270 g modified plasma phospholipid fatty acid (PLFA) proportions of ω3 and ω6 in a
level associated with decreased risk for CVD [73]. In addition, supplementation of marine PLs rich
in ω3 PUFA in prostate cancer patients resulted in a favourable increase of EPA and DHA in blood
lipids, while AA (ω6 PUFA) decreased significantly, suggesting a mechanism for a lower incidence of
metastatic progression in prostate cancer patients with high consumption of fish containing PLs rich in
ω3 PUFA [74].
Taking into account all the above, in combination with the strong antithrombotic effects of the
FGE-salmon-PLs extract against both PAF and thrombin pathways, one may suggest that this extract
may be a promising candidate for the development of novel cardioprotective food supplements and
nutraceuticals. In addition, such extracts rich in bioactive PLs baring ω3 PUFA can also be used
effectively in other inflammation-related disorders [5]. Of interest are the disorders of the central
nervous system, since such bioactive lipids can more effectively reach and surpass the blood–brain
barrier [5].
However, ex vivo and in vivo studies are required to further support such a notion. Nevertheless,
the fact that these FGE-salmon-PL extracts were derived from a sustainable salmon source, with
the use of food-grade solvents is a promising supportive element towards its future use as a food
supplement and nutraceutical, to be tested in clinical trials in several inflammation-related disorders,
including CVD.
4. Materials and Methods
4.1. Materials and Instrumentation
All glass and plastic consumables, reagents, and solvents were of analytical grade and were purchased
from Fisher Scientific Ltd. (Dublin, Ireland). Evacuated sodium citrate S-monovettes and 20G safety
needles for blood sampling were purchased from Sarstedt Ltd (Wexford, Ireland). The preparative
TLC glass plates (20 × 20 cm) with silica gel G-60 and 1.0/2.0 mm thickness were purchased from
Merck (Darmstadt, Germany). The platelet aggregation bioassay was carried out on a Chronolog-490
two-channel turbidimetric platelet aggregometer (Havertown, PA, USA), coupled to the accompanying
AGGRO/LINK software package. All platelet aggregation consumables were purchased from
Labmedics LLP (Abingdon on Thames, UK). Standard PAF, thrombin, egg phospholipid extract,
and BSA were purchased from Sigma Aldrich (Wicklow, Ireland). Centrifugations were carried out on
an Eppendorf 5702R centrifuge (Eppendorf Ltd., Stevenage, UK). Spectrophotometric analysis was
carried out on a Shimadzu UV-1800 spectrophotometer (Kyoto, Japan).
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4.2. Salmon Samples Assessed
A sustainable marine source was chosen for this study; Irish organic farmed salmon (Salmo salar).
All salmon fillets were provided by the same supplier, Marine Harvest (Co. Donegal, Ireland). More
specifically, the Irish organic farmed salmon used in this study was produced at the Marine Harvest
farming facilities with a diet containing only organic approved natural ingredients from sustainable
sources, with fish meal and oil derived from the trimmings of fish caught for human consumption.
All ingredients were free from genetically modified organisms. Fish were reared in large pens which
allowed them to follow their natural shoaling behaviour. Pens contained less than 10 kg/m3, which is
less than half that of conventional farms. The production sites were continuously flushed with clean
water, preventing any build-up of parasites or pollutants. This natural, healthy environment and low
population density allowed the fish to develop good muscle tone and body shape. All salmon fillets
tested were harvested at the same time (same lot number) within the Marin Harvest farming facilities.
Therefore, for the comparison between the CE-salmon-PLs and FGE-Salmon-PLs, all analyses on all of
the extracts were conducted on salmon fillets from the same batch of farmed salmon.
4.3. Isolation of FGE-Salmon-PLs from Salmon Fillets
Several (n = 6) 100 g samples of the fresh salmon fillets were homogenised mechanically by a
Waring blender (Fisher Scientific Ltd, Dublin, Ireland) and their total lipids (TL) were extracted and
further separated into their neutral lipids (NL) fraction and the polar lipids fraction (FGE salmon-PLs)
using food-grade solvents, namely water, ethanol, and hexane (all of HPLC grade), according to EU
legislation for food-grade based extractions of fish oil (consolidated Directive 2009/32/EC: https:
//eur-lex.europa.eu/legal-content/en/ALL/?uri=CELEX:32009L0032). Solvents were evaporated
from the samples using flash rotary evaporation (Buchi Rotavapor, Mason Technology, Dublin, Ireland)
and lipid samples were transferred into small glass vials, where all the remaining solvents were further
evaporated under a stream of nitrogen. The acquired FGE-salmon-PL extracts were weighed and
stored under a nitrogen atmosphere in −20 ◦C for further analysis.
4.4. Fractionation of FGE-Salmon-PLs to Subclasses by Preparative TLC
The TLC analysis of the FGE-salmon-PLs was performed as previously described [16]. Briefly, up
to 50 mg of TPL was applied to the TLC plates. An elution system consisting of chloroform:methanol:
water 65:35:6 (v/v/v), was utilised for the separation of FGE-salmon-PLs. Subsequently, the plates were
stained under iodine vapours. Six major bands appeared after the separation of the FGE-salmon-PLs.
Following the evaporation of the iodine vapours, the bands were scraped, and lipids were extracted
from the silica gel according to the Bligh and Dyer method [20]. The chloroform phase was evaporated
to dryness under nitrogen and lipids were weighed, re-dissolved in 1 mL of chloroform:methanol 1:1
(v/v), and stored at −20 ◦C in a nitrogen atmosphere until further analysis.
4.5. Human Platelet-Rich Plasma (hPRP) Aggregation Studies of FGE-Salmon-PLs
All experiments were conducted as previously described [16]. Briefly, for hPRP isolation, healthy
human volunteers (n = 10) donated fasting blood samples. The Ethics Committee of the University of
Limerick approved the protocol and it was performed in accordance with the Declaration of Helsinki.
Healthy donors were fully aware that their blood samples were used in our study and written consent
was provided to the specialised phlebotomist. The blood samples were in sodium citrate anticoagulant
and were centrifuged at 194 g for 18 min at 24 ◦C with no brake applied. The supernatant hPRP was
then transferred to polypropylene tubes at room temperature for the aggregation bioassays, whereas
platelet-poor plasma (PPP) was obtained by further centrifuging the specimens at 1465 g for 20 min at
24 ◦C with no brake applied. hPRP was adjusted to 500,000 platelets/µL if required by addition of the
respective volume of PPP according to the absorbance of the hPRP measured in spectrophotometer.
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Aliquots of standard PAF solution in chloroform/methanol (1:1 v/v) were evaporated under
a stream of nitrogen and re-dissolved in bovine serum albumin (BSA; 2.5 mg BSA/mL saline)
into cuvettes to obtain PAF solutions with final concentrations ranging from 2.6 × 10−8 to
2.6 × 10−5 mol/L. The examined salmon PL samples were also dissolved in BSA (2.5 mg BSA/mL
saline). Standard active thrombin was dissolved in saline prior to testing. The maximum
reversible PAF-induced/thrombin-induced platelet aggregation was determined as 100% aggregation,
that was also used as baseline (0% inhibition), by adding PAF at approximately 2.6 × 10−8 M
final concentration or thrombin at approximately 0.01–0.4 U/mL in the aggregometer cuvette.
The PAF-induced/thrombin-induced aggregation was calculated first at 0% inhibition of baseline
in a cuvette, whereas after the pre-incubation of hPRP with the test samples in a variety of
concentrations in a different cuvette, the same amount of PAF/thrombin was added, and the
reduced aggregation was calculated. Thus, a linear curve at the 20–80% range of the percentage
of inhibition against PAF-induced/thrombin-induced aggregation of hPRP to the concentrations
of each sample was deduced. From this curve, the concentration of the sample that led to 50%
of PAF-induced/thrombin-induced aggregation of hPRP was calculated as the 50% inhibitory
concentration value, also known as the IC50 value for each sample. All experiments were performed in
triplicate (n = 3), using a different donors blood sample for each replicate, to ensure reproducibility.
The resulting IC50 values were expressed as a mean value of the mass of lipid (µg) in the aggregometer
cuvette ± standard deviation (SD).
4.6. LC-MS Analysis of FGE-Salmon-PLs
FGE-salmon-PLs and the most bioactive TLC-derived lipid fractions (corresponding to the PC
and PE lipid subclasses) against both the PAF pathway and the thrombin pathway, and the FFAs that
were derived from their saponification, were further analysed by LC-MS as previously described [16].
Briefly, each of these lipid samples was separated into two half parts and dried in a N2 stream.
The first half of each sample was saponified by adding 1.5 mL of saponification reagent, (2.5 M KOH:
methanol (1:4, v/v)), which was gently vortexed. The vials were incubated at 72 ◦C for 15 min prior to
the addition of 225 µL of formic acid. Then, 1725 µL of chloroform and 375 µL of Milli-Q water were
added, and vortexed to separate the two layers. The chloroform layer containing free fatty acids was
transferred carefully to amber vials and evaporated to dryness before being stored at −20 ◦C until
LC-MS analysis.
Before LC-MS analysis, all of the dried lipids were re-constituted in 500 µL of methanol:
dichloromethane (2:1, v/v), centrifuged at 13,793 g for 6 min (Heraeus Biofuge Stratos, Fisher Scientific
Ltd., Dublin, Ireland) prior to filtering through 3 kDa ultra-centrifuge filters (Amicon Ultra 3k, Merck
Millipore Ltd., Carrigtwohill, Co. Cork, Ireland). Polar lipid and free fatty acid profiles were obtained
in a HPLC (Agilent 1260 series, Agilent Technologies Ireland Ltd., Little Island, Co. Cork, Ireland)
equipped with a Q-TOF mass spectrometer (Agilent 6520) and the source type was electrospray
ionization (ESI). The column used for separations was an Agilent C18 Poroshell 120 column (2.7 µm,
3.0 × 150 mm). The composition of the mobile phase (A) was 2 mM ammonium acetate in water and
2 mM ammonium acetate in 95% acetonitrile for the mobile phase (B). Chromatographic separation
was performed by gradient elution starting with 60% B for 1 min, then increasing to 90% B over
2.5 min. Subsequently, 90% B was held for 1.5 min and increased afterwards to 100% over 5 min.
Then, 100% B was held for 4 min, reducing afterwards to 60% B over 0.5 min and held for 1 min
until the next run. The mobile phase flow rate was 0.3 mL/min until 5 min elapsed, increasing up to
0.6 mL/min after 10 min and held at this flow rate until the end of the run. The injection volume was
10 µL. The mass spectrometer was operated in negative ionization mode, scanning the lipids from m/z
50–1100. Drying gas flow rate, temperature, and nebuliser pressure were at 5 L min−1, 325 ◦C, and
30 psi, respectively. Fragmentor and skimmer voltages were kept at 175 V and 65 V, respectively, and
the capillary voltage was 3500 V. In the negative ion mode, the monitoring reference masses used were
1033.988 and 112.9855, respectively.
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The assignment of free fatty acids and phospholipid species was based upon a combination of
survey, daughter, precursor, and neutral loss scans. The identity of phospholipid species was verified
using the LIPID MAPS: Nature Lipidomics Gateway (www.lipidmaps.org), by using the lowest delta
values combined with the results obtained from the LC-MS analysis of the FFA that were produced by
their saponification.
4.7. Statistical Analysis
One-way analysis of variance (ANOVA) was used in order to find the significant differences
between IC50 values against PAF- and thrombin-induced platelet aggregation of all the samples tested,
but also when these values were compared with previously reported ones for the CE-salmon-PLs [19].
Differences were considered to be statistically significant when the p-value was less than 0.05. The
data were analysed using a statistical software package (IBM-SPSS statistics 24 for Windows, SPSS Inc.,
Chicago, IL, USA).
5. Conclusions
We have previously described that several marine sources, including salmon, contain bioactive
PLs with strong antithrombotic and anti-atherogenic cardioprotective activities [4,13–16,18,19,22].
However, such PL extracts were previously obtained from these sources by using conventional
extractions with non-food-grade solvents such as chloroform and petroleum ether [20,21]. Thus,
such CE-salmon-PLs extracts cannot be used in human-based trials and dietary interventions or for
developing novel food supplements and nutraceuticals.
To the best of our knowledge, this is the first study to report that PLs derived from salmon
using food-grade solvents in compliance with current EU legislations exhibited strong antithrombotic
activities against both the PAF and thrombin pathways of platelet aggregation. Remarkably, the
FGE-salmon-PLs extract, as well as each one of its most bioactive lipid subclasses (PC and PE),
exhibited much higher anti-thrombin effects than the relative CE-salmon-PLs extract. Moreover,
our LC-MS-based structure–activity relationship studies revealed that the existence of not only
DHA but also EPA at the sn-2 position of specific subspecies of bioactive diacyl- or alkyl-acyl- PC
and PE moieties, seem to be related to the more potent anti-thrombin activities observed in the
FGE-salmon-PLs, in contrast to the anti-thrombin activities of CE-salmon-PLs.
Taking into account that both thrombin and PAF are potent mediators implicated in inflammatory
manifestations related to endothelial dysfunction and the genesis and progression of atherosclerosis
and subsequent cardiovascular disorders [5], our results indicate that the FGE-salmon-PLs are strong
candidates for the development of cardioprotective supplements and nutraceuticals. However,
pre-clinical/clinical studies are required in order to acquire evidence for the in vivo beneficial effects
of such FGE-salmon-PLs-based food supplements and nutraceuticals.
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